查看文章

[1] Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmacytoid dendritic cell neoplasm. Hematology Meeting Reports (formerly Haematologica Reports); 2009 [Online] 3: 3 [2] Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124 (3): 385–392.[3] Pemmaraju N, Kantarjian HM, Cortes JE, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a large single-center experience: analysis of clinical and molecular characteristics and patient outcomes. Blood. 2015; 126 (23): Abstract 3746 [4] Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015; 125 (23): 3559–3562.[5] Shepro D, Miller M. Gemcitabine in Blastic Plasmacytoid Dendritic cell neoplasm …